Tania Vanzolini

Tania Vanzolini


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TVTania Vanzolini
Tania Vanzolini
MBMichela Bruschi
Michela Bruschi
Andrea RinaldiAndrea Rinaldi
Andrea Rinaldi
Mauro MagnaniMauro Magnani
Mauro Magnani
AFAlessandra Fraternale
Alessandra Fraternale
Despite the great strides in healthcare during the last century, some challenges still remained unanswered. The development of multi-drug resistant bacteria, the alarming growth of fungal infections, the emerging/re-emerging of viral diseases are yet a worldwide threat. Since the discovery of natural antimicrobial peptides able to broadly hit several pathogens, peptide-based therapeutics have been under the lenses of the researchers. This review aims to focus on synthetic peptides and elucidate their multifaceted mechanisms of action as antiviral, antibacterial and antifungal agents. Antimicrobial peptides generally affect highly preserved structures, e.g., the phospholipid membrane via pore formation or other constitutive targets like peptidoglycans in Gram-negative and Gram-positive bacteria, and glucan in the fungal cell wall. Additionally, some peptides are particularly active on biofilm destabilizing the microbial communities. They can also act intracellularly, e.g., on protein biosynthesis or DNA replication. Their intracellular properties are extended upon viral infection since peptides can influence several steps along the virus life cycle starting from viral receptor-cell interaction to the budding. Besides their mode of action, improvements in manufacturing to increase their half-life and performances are also taken into consideration together with advantages and impairments in the clinical usage. Thus far, the progress of new synthetic peptide-based approaches is making them a promising tool to counteract emerging infections.

19 January 2024 in Applied Microbiology and Biotechnology
Verified
Journal Article
Open access
PDF file
TVTania Vanzolini
Tania Vanzolini
MMMauro Magnani
Mauro Magnani
Fungal infections represent a serious global health threat. The new emerging pathogens and the spread of different forms of resistance are now hardly challenging the tools available in therapy and diagnostics. With the commonly used diagnoses, fungal identification is often slow and inaccurate, and, on the other hand, some drugs currently used as treatments are significantly affected by the decrease in susceptibility. Herein, the antifungal arsenal is critically summarized. Besides describing the old approaches and their mechanisms, advantages, and limitations, the focus is dedicated to innovative strategies which are designed, identified, and developed to take advantage of the discrepancies between fungal and host cells. Relevant pathways and their role in survival and virulence are discussed as their suitability as sources of antifungal targets. In a similar way, molecules with antifungal activity are reported as potential agents/precursors of the next generation of antimycotics. Particular attention was devoted to biotechnological entities, to their novelty and reliability, to drug repurposing and restoration, and to combinatorial applications yielding significant improvements in efficacy. Key points: • New antifungal agents and targets are needed to limit fungal morbidity and mortality. • Therapeutics and diagnostics suffer of delays in innovation and lack of targets. • Biologics, drug repurposing and combinations are the future of antifungal treatments.

14 February 2023 in RSC Advances
Verified
Journal Article
Open access
PDF file
TVTania Vanzolini
Tania Vanzolini
TMTomas Di Mambro
Tomas Di Mambro
Mauro MagnaniMauro Magnani
Mauro Magnani
MMMichele Menotta
Michele Menotta
AFM data about C. auris topography, surface biochemistry and nanomechanics are good indicators for the evaluation of the effects of the humanized monoclonal antibody H5K1 alone and in combination with commercially available antifungal drugs.

31 October 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TMTomas Di Mambro
Tomas Di Mambro
TVTania Vanzolini
Tania Vanzolini
MBMarzia Bianchi
Marzia Bianchi
RCRita Crinelli
Rita Crinelli
BCBarbara Canonico
Barbara Canonico
Mauro MagnaniMauro Magnani
Mauro Magnani
The resistance and the birth of new intrinsic and multidrug-resistant pathogenic species likeC.aurisis creating great concern in the antifungal world. Given the limited drug arsenal and the lack of effectiveness of the available compounds, there is an urgent need for innovative approaches. The murine mAb 2G8 was humanized and engineeredin silicoto develop a single-chain fragment variable (hscFv) antibody against β-1,3-glucans which was then expressed inE.coli. Among the recombinant proteins developed, a soluble candidate with high stability and affinity was obtained. This selected protein is VL-linker-VH oriented, and it is characterized by the presence of two ubiquitin monomers at the N-terminus and a His tag at the C-terminus. This construct, Ub2-hscFv-His, guaranteed stability, solubility, efficient purification and satisfactory recovery of the recombinant product. HscFv can bind β-1,3-glucans both as coated antigens and onC.aurisandC.albicanscells similarly to its murine parental and showed long stability and retention of binding ability when stored at 4°, -20° and -80° C. Furthermore, it was efficient in enhancing the antifungal activity of drugs caspofungin and amphotericin B againstC.auris. The use of biological drugs as antifungals is limited; here we present a promising hscFv which has the potential to be useful in combination with currently available antifungal drugs.

15 April 2026 in npj Antimicrobials and Resistance
Verified
Journal Article
Open access
TVTania Vanzolini
Tania Vanzolini
VFValentina Fiori
Valentina Fiori
MMMauro Magnani
Mauro Magnani
Fungal infections pose a major worldwide health risk, as newly emerging pathogens and the increasing spread of drug resistance are now severely challenging current therapeutic and diagnostic tools. Candidozyma auris embodies both of these aspects as it is an urgent threat that is resistant to several antifungal classes. The lack of effective drugs is driving the development of innovative strategies, among them monoclonal antibodies. This study investigates the in vivo and ex vivo safety and efficacy of the humanized monoclonal antibody Dia-T51, administered alone or in combination with amphotericin B (AMB), in Galleria mellonella model. Against C. auris infection, Dia-T51 demonstrated good therapeutic efficacy and provided near-complete protection when used prophylactically. The synergy between Dia-T51 and AMB observed in vitro was confirmed in vivo, resulting in enhanced larval survival and a significant reduction in fungal burden. The results strengthen the profile of Dia-T51 as a promising biological agent against fungal infections both for its standalone potential (via direct inhibition and immune-mediated mechanisms) and for its ability to amplify the efficacy of conventional antifungals.

5 May 2026 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
TVTania Vanzolini
Tania Vanzolini
VFValentina Fiori
Valentina Fiori
TMTomas Di Mambro
Tomas Di Mambro
MMMauro Magnani
Mauro Magnani
Developing effective antibody therapeutics requires not only high affinity, specificity, and potency but also optimal stability and safety. Comprehensive biophysical and biochemical profiling acts as an essential gatekeeper to predict the fate of a candidate and facilitate the transition from bench to bedside. This study evaluates the developability of Dia-T51, an anti-β-1,3-glucan monoclonal antibody humanized from the murine parental 2G8 and designed for antifungal therapy. We employed a multi-technique approach combining UV-Visible, Fluorescence, and Circular Dichroism spectroscopy with in silico molecular modeling to elucidate the mechanisms involved in antigen binding. Our analysis revealed a fundamental divergence between the "conformational frustration" and thermodynamic strain exhibited by 2G8 and the cooperative "induced fit" mechanism facilitated by the backbone plasticity of Dia-T51. This structural adaptability resulted in superior affinity and thermal stability for the Dia-T51-antigen complex compared to its murine counterpart. Complementary stability assessments demonstrated that Dia-T51 remains free of aggregates and undergoes a structural refinement under physiological stress. Furthermore, samples from a 3-year-old stock of Dia-T51 were subjected to accelerated stability testing to challenge in silico predictions of chemical liabilities within the variable regions. Despite the emergence of minor stress-related structural markers detected by Dynamic Light Scattering and SDS-PAGE, the antibody retained a predominant monomeric profile and high antigen-binding capacity, as confirmed by Surface Plasmon Resonance and ELISA. These findings demonstrate that Dia-T51 possesses the structural resilience and functional robustness required for successful clinical translation, validating its potential for downstream pharmaceutical development and the importance of integrating biophysical data into developability assessments.